MCID: ASP030
MIFTS: 43

Aspirin Resistance

Categories: Cardiovascular diseases, Blood diseases

Aliases & Classifications for Aspirin Resistance

MalaCards integrated aliases for Aspirin Resistance:

Name: Aspirin Resistance 57
Aspirin, Resistance to Cardioprotective Effect of 57
Aspirin, Resistance to Antithrombotic Effect of 57
Aspirin Cardioprotective Effect of 57
Aspirin Antithrombotic Effect of 57

Classifications:



External Ids:

OMIM 57 608223

Summaries for Aspirin Resistance

OMIM : 57 Aspirin (acetylsalicylic acid) is a classic nonsteroidal antiinflammatory agent that irreversibly inhibits type I cyclooxygenase (PTGS1, or COX1; 176805) in platelets, resulting in decreased production of thromboxane A2 (TXA2) and inhibition of platelet aggregation. Because of this feature, it is used therapeutically to prevent cardiothrombotic events. Individuals show a variable response to the drug, referred to as aspirin ineffectiveness or resistance, in which not all individuals or populations appear to receive the full prophylactic or therapeutic benefits (summary by Zhou et al., 2011). Halushka and Halushka (2002) discussed a possible basis for resistance to the cardioprotective effect of aspirin. (608223)

MalaCards based summary : Aspirin Resistance, also known as aspirin, resistance to cardioprotective effect of, is related to myocardial infarction and active peptic ulcer disease. An important gene associated with Aspirin Resistance is PTGS1 (Prostaglandin-Endoperoxide Synthase 1), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Development VEGF signaling via VEGFR2 - generic cascades. The drugs Aspirin and Clopidogrel have been mentioned in the context of this disorder. Affiliated tissues include testes, heart and kidney, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Aspirin Resistance

Graphical network of the top 20 diseases related to Aspirin Resistance:



Diseases related to Aspirin Resistance

Symptoms & Phenotypes for Aspirin Resistance

Clinical features from OMIM:

608223

MGI Mouse Phenotypes related to Aspirin Resistance:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.91 APOB F13A1 ITGB3 PTGS1 PTGS2 TBXA2R
2 homeostasis/metabolism MP:0005376 9.85 APOB F13A1 ITGB3 PTGS1 PTGS2 TBXA2R
3 hematopoietic system MP:0005397 9.8 F13A1 ITGB3 PTGS1 PTGS2 TBXA2R
4 mortality/aging MP:0010768 9.73 APOB F13A1 ITGB3 PTGS1 PTGS2 TBXA2R
5 immune system MP:0005387 9.72 APOB ITGB3 PTGS1 PTGS2 TBXA2R
6 muscle MP:0005369 9.46 APOB ITGB3 PTGS1 PTGS2
7 reproductive system MP:0005389 9.43 APOB F13A1 ITGB3 PTGS1 PTGS2 TBXA2R
8 respiratory system MP:0005388 9.02 F13A1 ITGB3 PTGS1 PTGS2 TBXA2R

Drugs & Therapeutics for Aspirin Resistance

Drugs for Aspirin Resistance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 67)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-78-2 2244
2
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Not Applicable 120202-66-6, 113665-84-2 60606
3
Ticlopidine Approved Phase 4,Phase 3,Phase 2 55142-85-3 5472
4
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
5
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
6
Racepinephrine Approved Phase 4 329-65-7 838
7
Dipyridamole Approved Phase 4 58-32-2 3108
8
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
9
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
10
Tirofiban Approved Phase 4,Phase 2 144494-65-5 60947
11
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
12
Pravastatin Approved Phase 4 81093-37-0 54687
13 Acetylsalicylic acid lysinate Phase 4
14 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
17 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Antipyretics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Fibrinolytic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Vasodilator Agents Phase 4
25 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
26 Purinergic P2 Receptor Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
27 Purinergic P2Y Receptor Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
28 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
29 Anti-Asthmatic Agents Phase 4
30 Autonomic Agents Phase 4
31 Bronchodilator Agents Phase 4
32 Neuroprotective Agents Phase 4
33 Phosphodiesterase 3 Inhibitors Phase 4
34 Phosphodiesterase Inhibitors Phase 4
35 Protective Agents Phase 4,Phase 2
36 Respiratory System Agents Phase 4
37 Epinephryl borate Phase 4
38 Aspirin, Dipyridamole Drug Combination Phase 4
39 Adjuvants, Immunologic Phase 4,Phase 2
40 Anti-Bacterial Agents Phase 4,Phase 2
41 Antibiotics, Antitubercular Phase 4,Phase 2
42 Anti-Infective Agents Phase 4,Phase 2
43 Antiviral Agents Phase 4,Phase 2
44 calcium heparin Phase 4
45 Interferon Inducers Phase 4,Phase 2
46 interferons Phase 4,Phase 2
47 Krestin Phase 4,Phase 2
48 Radiation-Protective Agents Phase 4,Phase 2
49 Anticholesteremic Agents Phase 4
50 Antimetabolites Phase 4

Interventional clinical trials:

(show top 50) (show all 52)
# Name Status NCT ID Phase Drugs
1 Aspirin Resistance Reversibility in Diabetic Patients Unknown status NCT01935193 Phase 4 lysine acetylsalicylate
2 Aspirin in the Prevention of Cardiovascular Events in Hemodialysis Patients Unknown status NCT01198379 Phase 4 aspirin;Placebo
3 Antiaggregation in Primary Prevention of Vascular Access for Hemodialysis Unknown status NCT02055131 Phase 4 aspirin
4 Type 2 Diabetes Mellitus and Atherosclerosis Unknown status NCT01250340 Phase 4 Aspirin;Placebo
5 Overcome Biochemical Aspirin Resistance Through Cilostazol Combination Completed NCT00446641 Phase 4 Cilostazol;placebo
6 Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting Completed NCT01159639 Phase 4 Clopidogrel
7 Platelet Hyperreactivity to Aspirin and Stroke Completed NCT00766896 Phase 4 Aspirin (platelet sensitive versus platelet hyperreactivity)
8 Aspirin Responsiveness in Women at Risk for Cardiac Events Completed NCT00818337 Phase 4 Aspirin
9 Modified-release Dipyridamole/Aspirin (200mg/25mg bd) Versus Aspirin (75mg) in Aspirin-resistant Patients Completed NCT00129038 Phase 4 modified-release dipyridamole/aspirin;aspirin
10 Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance Completed NCT00398463 Phase 4 Tirofiban;Placebo
11 Resistance to Aspirin and/or Clopidogrel Among Patients With PAD. Completed NCT00262561 Phase 4 Aspirin
12 Trial to Assess the Efficacy of Combination Formula of Aspirin Plus Clopidogrel in Patients With Coronary Stent Completed NCT02410083 Phase 4 Clopirin 1;Clopidogrel-Aspirin(co-administration) 1;Clopirin 2;Clopidogrel-Aspirin(co-administration) 2
13 Aspirin Non-responsiveness and Clopidogrel Endpoint Trial. Completed NCT00222261 Phase 4 aspirin;clopidogrel
14 Studies of Traditional Chinese Medicine Clinical Efficacy Evaluation Index Completed NCT01502943 Phase 4 Louxiangdan Tongxin granules;TCM granules placebo;Chixiangshen Tongxin granules;TCM granule placebo plus western basis treatment;Western basis treatment
15 Clinical Management of Antiplatelet Drug Resistance in Patients With Drug Eluting Coronary Stents Withdrawn NCT00589862 Phase 4 Plavix (Clopidogrel)
16 Thromboelastography As An Assessment Tool for Possible Clopidogrel and Aspirin Resistance Unknown status NCT00697021 Phase 3 Aspirin (200mg) and/or Plavix (150mg) dosage according to TEG;Aspirin 100mg and Plavix 75mg
17 ThrombElastoGraphic Haemostatic Status and Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery Unknown status NCT01046942 Phase 3 Clopidogrel+acetylsalicylic acid;acetylsalicylic acid
18 Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events Completed NCT01586975 Phase 2, Phase 3 Clopidogrel;Aspirin 81 mg;Aspirin >300 mg
19 The Effects of Omega-3 Fatty Acids on Aspirin Resistance Completed NCT00771914 Phase 1, Phase 2 Aspirin;Lovaza;Both Aspirin and Lovaza
20 Aspirin Resistance and Percutaneous Coronary Intervention (PCI) Completed NCT01103440 Phase 2 Intravenous Glycoprotein inhibitor + ASA, Clopidogrel;Antiplatelet Therapy (ASA, Clopidogrel)
21 Fish Oil and Aspirin With Type 2 Diabetes Completed NCT01181882 Phase 2
22 Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial. Completed NCT02280031 Phase 2 Acetylsalicylic Acid;Placebo
23 In-Vivo Bleeding Volume Test for Platelet-Aspirin Interaction Unknown status NCT01047722 Phase 1 Aspirin ingestion followed by doing a Bleeding Volume Test
24 Mechanism Based Resistance to Aspirin Completed NCT00948987 Phase 1 Aspirin
25 Aspirin Resistance in Systemic Lupus Erythematosus (SLE) Completed NCT00731302 Phase 1 aspirin and meloxicam
26 Aspirin Resistance and Prognosis of Patients With Critical Limb Ischaemia Unknown status NCT01104441
27 Investigation of Platelet Function and Aspirin Resistance in Chronic Dialysis Patient Unknown status NCT01045785
28 Prevalence and Level of Thienopyridine Resistance Seen in a Contemporary Percutaneous Coronary Intervention or Coronary Artery Bypass Graft Population Unknown status NCT01408927
29 Platelet Reactivity and MES During CEA Unknown status NCT01547039
30 Relationship Between Level of Hemoglobin A1c and Platelet Function in Patients Undergoing Cardiac Surgery Unknown status NCT02711124
31 Prevalence and Profile of Aspirin Resistance in Hemodialysis Patients Completed NCT00792272
32 Prevalence of Aspirin Resistance in Chronic Kidney Disease Patients Completed NCT01364779
33 The Effect of Serum LDL Lowering on Aspirin Resistance Completed NCT00466154 Not Applicable Aspirin
34 Danish Aspirin Resistance Trial - Pilot Study Completed NCT00389129 Not Applicable acetylsalicylic acid
35 Aspirin Resistance in Coronary Artery Disease Completed NCT00753935 Early Phase 1 enteric-coated aspirin;Chewable aspirin
36 Laboratory Aspirin Resistance in Diabetics and Non-Diabetics Completed NCT00563875 Not Applicable acetylsalicylic acid
37 The Study on Profile and Genetic Factors of Aspirin Resistance (ProGEAR Study) Completed NCT00250380
38 Enteric Coating as a Factor in Aspirin Resistance Completed NCT00531362 Plain aspirin
39 Effect of Glucose Control on the Response to Aspirin in Type 2 Diabetic Patients Completed NCT00649909
40 The Efficacy of Aspirin in the Postoperative Period in Vascular Surgery Completed NCT01432652
41 Genotypic and Phenotypic Correlates of Resistance to Aspirin Completed NCT01361620 Not Applicable aspirin
42 Aspirin Responsiveness and Outcome in Coronary Artery Bypass Graft (CABG) Surgery Completed NCT01174862
43 Optimum Platelet Inhibition After Coronary Bypass Surgery Completed NCT00262275 Not Applicable Aspirin, Clopidogrel
44 Aspirin Responsiveness in Women With Coronary Artery Disease Completed NCT01406990
45 Platelet Reactivity In Patients With Nuisance Bleeding On A Thienopyridine Completed NCT01152229
46 The Bochum Optimizing Clopidogrel-Aspirin Therapy and MORTality Study (BOCLA-Mort) Completed NCT01796691
47 Resistance on Antithrombotic Drugs in Ischemic Heart Disease Completed NCT00742430
48 Validation of an Assay to Measure Cyclooxygenase-1 Activity Completed NCT00761891 Not Applicable Enteric-coated aspirin;Chewable aspirin
49 Aspirin Resistance and Sleep Apnea in Type-2 Diabetic Patients Recruiting NCT01788930 Not Applicable
50 Aspirin Resistance Following Coronary Bypass Surgery Terminated NCT00260377 Not Applicable

Search NIH Clinical Center for Aspirin Resistance

Genetic Tests for Aspirin Resistance

Anatomical Context for Aspirin Resistance

MalaCards organs/tissues related to Aspirin Resistance:

41
Testes, Heart, Kidney

Publications for Aspirin Resistance

Articles related to Aspirin Resistance:

(show top 50) (show all 81)
# Title Authors Year
1
Aspirin Resistance: Risk Factors and Prognostic Significance in Patients with Cerebral Small Vessel Disease. ( 29530996 )
2018
2
The Relationship Between Aspirin Resistance and Carotid Imaging in Young Patients With ST-Segment Elevated Myocardial Infarction: A Cross-Sectional Study. ( 29888621 )
2018
3
Aspirin Resistance: Cardiovascular Risk Game Changer. ( 29757761 )
2018
4
Effects of Ramadan fasting on aspirin resistance in type 2 diabetic patients. ( 29529091 )
2018
5
Global Trends in Aspirin Resistance-Related Research from 1990 to 2015: A Bibliometric Analysis. ( 28667787 )
2017
6
Genetic signatures in ischemic stroke: Focus on aspirin resistance. ( 28969559 )
2017
7
Suspected aspirin resistance in individual healthy adult warmblood horses. ( 28390056 )
2017
8
My Approach to the patient with CAD and aspirin resistance. ( 28865598 )
2017
9
Aspirin resistance are associated with long-term recurrent stroke events after ischaemic stroke. ( 28842303 )
2017
10
Interaction among COX-2, P2Y1 and GPIIIa gene variants is associated with aspirin resistance and early neurological deterioration in Chinese stroke patients. ( 28068952 )
2017
11
Association of GPIa and COX-2 gene polymorphism with aspirin resistance. ( 28948649 )
2017
12
Targeting aspirin resistance with nutraceuticals: a possible strategy for reducing cardiovascular morbidity and mortality. ( 28912955 )
2017
13
The incidence of aspirin resistance in heart transplantation recipients. ( 28747943 )
2017
14
Over-expression of cyclooxygenase-2 in increased reticulated platelets leads to aspirin resistance after elective off-pump coronary artery bypass surgery. ( 29149707 )
2017
15
Decreased turnover aspirin resistance by bidaily aspirin intake and efficient cytoreduction in myeloproliferative neoplasms. ( 29090588 )
2017
16
Post-pregnancy aspirin resistance appears not to be related with recurrent hypertensive disorders of pregnancy. ( 28033561 )
2017
17
rs5911 and rs3842788 Genetic Polymorphism, Blood Stasis Syndrome, and Plasma TXB2 and hs-CRP Levels Are Associated with Aspirin Resistance in Chinese Chronic Stable Angina Patients. ( 28465708 )
2017
18
Prevalence of aspirin resistance in patients with type II diabetes: a descriptive-analytical studya8c. ( 28025961 )
2017
19
Biochemical aspirin resistance is associated with increased stroke severity and infarct volumes in ischemic stroke patients. ( 29100372 )
2017
20
Platelet Carbonic Anhydrase II, a Forgotten Enzyme, May Be Responsible for Aspirin Resistance. ( 29090039 )
2017
21
PFA-100-measured aspirin resistance is the predominant risk factor for hospitalized cardiovascular events in aspirin-treated patients: A 5-year cohort study. ( 29055181 )
2017
22
Aspirin resistance in coronary heart disease: Current understandings and strategies. ( 28191510 )
2016
23
The effectiveness of antioxidant therapy in aspirin resistance, diabetes population for prevention of thrombosis. ( 27393925 )
2016
24
Aspirin Resistance Predicts Adverse Cardiovascular Events in Patients with Symptomatic Peripheral Artery Disease. ( 28100965 )
2016
25
Aspirin resistance in cerebrovascular disease and the role of glycoprotein IIIa polymorphism in Turkish stroke patients. ( 26809135 )
2016
26
Interaction between COX-1 and COX-2 Variants Associated with Aspirin Resistance in Chinese Stroke Patients. ( 27318652 )
2016
27
Platelet glycoprotein IIIa gene polymorphism (Leu33Pro) and aspirin resistance in a very elderly Chinese population. ( 24720773 )
2014
28
Effect of opium addiction on aspirin resistance in stable angina pectoris. ( 25140212 )
2014
29
Association of ALOX5AP1 SG13S114T/A variant with ischemic stroke, stroke subtypes and aspirin resistance. ( 23746795 )
2013
30
Protocol for a systematic review of the diagnostic and prognostic utility of tests currently available for the detection of aspirin resistance in patients with established cardiovascular or cerebrovascular disease. ( 23442317 )
2013
31
Frequency, risk factors, prognosis, and genetic polymorphism of the cyclooxygenase-1 gene for aspirin resistance in elderly Chinese patients with cardiovascular disease. ( 23038044 )
2013
32
Aspirin resistance in patients with type II diabetes mellitus. ( 24236750 )
2013
33
Association of COX-2 rs20417 with aspirin resistance. ( 22763923 )
2013
34
Genetic polymorphisms of HO-1 and COX-1 are associated with aspirin resistance defined by light transmittance aggregation in Chinese Han patients. ( 22609818 )
2013
35
Laboratory Aspirin Resistance and the Risk of Major Adverse Cardiovascular Events in Patients with Coronary Heart Disease on Confirmed Aspirin Adherence. ( 24201035 )
2013
36
Aspirin resistant patients with recent ischemic stroke. ( 24211052 )
2013
37
Interaction Between vWF Levels and Aspirin Resistance in Ischemic Stroke Patients. ( 24323374 )
2013
38
Aspirin resistance and ischemic heart disease on Iranian experience. ( 23210092 )
2012
39
[Correlation analysis of aspirin resistance and cycloxygenase-1 haplotype in old Chinese patients with cardio-cerebrovascular diseases]. ( 22860421 )
2012
40
Association of C3435T multi drug resistance gene-1 polymorphism with aspirin resistance in ischemic stroke and its subtypes. ( 22177087 )
2012
41
[Cyclooxigenase-1 gene polymorphism and aspirin resistance]. ( 23074965 )
2012
42
Microembolic signals and aspirin resistance in patients with carotid stenosis. ( 21883996 )
2012
43
Aspirin resistance, platelet turnover, and diabetic angiopathy: a 2011 update. ( 22142668 )
2012
44
Effect of polymorphism and type II diabetes on aspirin resistance in patients with unstable coronary artery disease. ( 21740787 )
2011
45
Impact of genetic polymorphisms on platelet function and aspirin resistance. ( 19923980 )
2010
46
Biochemical aspirin resistance and recurrent lesions in patients with acute ischemic stroke. ( 20606449 )
2010
47
Prothrombinase formation at the site of microvascular injury and aspirin resistance: the effect of simvastatin. ( 20074780 )
2010
48
Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease. ( 17917708 )
2009
49
Aspirin resistance determined with PFA-100 does not predict new thrombotic events in patients with stable ischemic cerebrovascular disease. ( 19084329 )
2009
50
Residual platelet thromboxane A2 and prothrombotic effects of erythrocytes are important determinants of aspirin resistance in patients with vascular disease. ( 18221358 )
2008

Variations for Aspirin Resistance

Expression for Aspirin Resistance

Search GEO for disease gene expression data for Aspirin Resistance.

Pathways for Aspirin Resistance

Pathways related to Aspirin Resistance according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.92 APOB F13A1 ITGB3 TBXA2R
2
Show member pathways
12.06 ITGB3 PTGS1 PTGS2
3
Show member pathways
11.91 APOB PTGS1 PTGS2
4
Show member pathways
11.65 PTGS1 PTGS2
5
Show member pathways
11.64 ITGB3 PTGS2
6 11.62 F13A1 PTGS2
7 11.61 PTGS1 PTGS2
8 11.52 ITGB3 PTGS1 TBXA2R
9 11.5 ITGB3 PTGS2
10 11.26 PTGS1 PTGS2
11 11.1 PTGS1 PTGS2 TBXA2R
12 10.99 PTGS1 PTGS2
13
Show member pathways
10.91 PTGS1 PTGS2
14 10.84 PTGS1 PTGS2
15 10.84 ITGB3 PTGS1 TBXA2R
16 10.79 PTGS1 PTGS2
17 10.65 PTGS1 PTGS2
18 10.5 PTGS1 PTGS2
19 10.25 PTGS1 PTGS2 TBXA2R

GO Terms for Aspirin Resistance

Cellular components related to Aspirin Resistance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 organelle membrane GO:0031090 8.62 PTGS1 PTGS2

Biological processes related to Aspirin Resistance according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 9.67 APOB PTGS1 PTGS2
2 inflammatory response GO:0006954 9.58 PTGS1 PTGS2 TBXA2R
3 platelet degranulation GO:0002576 9.54 F13A1 ITGB3
4 response to estradiol GO:0032355 9.52 APOB PTGS2
5 response to organic substance GO:0010033 9.51 APOB PTGS2
6 cellular oxidant detoxification GO:0098869 9.48 PTGS1 PTGS2
7 regulation of blood pressure GO:0008217 9.46 PTGS1 PTGS2
8 fatty acid biosynthetic process GO:0006633 9.43 PTGS1 PTGS2
9 positive regulation of vasoconstriction GO:0045907 9.37 PTGS2 TBXA2R
10 response to lipopolysaccharide GO:0032496 9.33 APOB PTGS2 TBXA2R
11 prostaglandin metabolic process GO:0006693 9.32 PTGS1 PTGS2
12 positive regulation of smooth muscle contraction GO:0045987 9.26 PTGS2 TBXA2R
13 prostaglandin biosynthetic process GO:0001516 8.96 PTGS1 PTGS2
14 cyclooxygenase pathway GO:0019371 8.62 PTGS1 PTGS2

Molecular functions related to Aspirin Resistance according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dioxygenase activity GO:0051213 9.16 PTGS1 PTGS2
2 peroxidase activity GO:0004601 8.96 PTGS1 PTGS2
3 prostaglandin-endoperoxide synthase activity GO:0004666 8.62 PTGS1 PTGS2

Sources for Aspirin Resistance

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....